MARKET

ABMD

ABMD

Abiomed Inc
NASDAQ
248.96
-1.09
-0.44%
After Hours: 248.96 0 0.00% 16:59 09/29 EDT
OPEN
246.69
PREV CLOSE
250.05
HIGH
249.86
LOW
243.52
VOLUME
390.59K
TURNOVER
0
52 WEEK HIGH
379.30
52 WEEK LOW
219.85
MARKET CAP
11.32B
P/E (TTM)
52.55
1D
5D
1M
3M
1Y
5Y
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
Zacks · 09/21 12:26
Multi-Center, Multi-Society Study Of Impella-Supported Patients With Cardiogenic Shock Due To Myocarditis In Japan Achieves 30-Day Survival Of 77%
Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with
Benzinga · 09/20 12:10
BRIEF-Abiomed Says Large, Multi-Center, Multi-Society Study Of Impella-Supported Patients Finds 30-Day AMI Cardiogenic Shock Survival Of 81%
BRIEF-Abiomed Says Large, Multi-Center, Multi-Society Study Of Impella-Supported Patients Finds 30-Day AMI Cardiogenic Shock Survival Of 81%
Reuters · 09/19 12:45
Abiomed Highlights Multi-Society Study Of Impella-supported Patients
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The
Benzinga · 09/19 12:07
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
BOSTON, September 17, 2022--Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
Business Wire · 09/17 13:02
U.S. FDA gives two approvals to Abiomed Impella heart pumps
Abiomed (NASDAQ:ABMD) <a href="https://seekingalpha.com/pr/18942495...
Seekingalpha · 09/16 13:23
BRIEF-FDA Approves Recover IV Randomized Controlled Trial With Exception From Informed Consent
BRIEF-FDA Approves Recover IV Randomized Controlled Trial With Exception From Informed Consent
Reuters · 09/16 12:07
Abiomed Announces FDA Approves RECOVER IV Randomized Controlled Trial With Exception From Informed Consent
Abiomed (NASDAQ:ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock
Benzinga · 09/16 12:05
More
About ABMD
ABIOMED, Inc. is a medical technology provider, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The Company's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.

Webull offers kinds of ABIOMED, Inc. stock information, including NASDAQ:ABMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABMD stock methods without spending real money on the virtual paper trading platform.